Effect of Magnesium L-Lactate on Blood Pressure in Patients with an Implantable Cardioverter Defibrillator

被引:6
作者
Baker, William L. [2 ]
Kluger, Jeffrey [3 ]
White, C. Michael [1 ]
Dale, Krista M. [4 ]
Silver, Burton B. [5 ]
Coleman, Craig I. [1 ,6 ]
机构
[1] Univ Connecticut, Sch Pharm, Hartford, CT 06102 USA
[2] Evidence Based Practice Ctr, Hartford, CT USA
[3] Hartford Hosp, Heart Rhythm Serv, Hartford, CT 06115 USA
[4] Baptist Hlth Syst, Jackson, MS USA
[5] Intracellular Diagnost, Medford, OR USA
[6] Hartford Hosp, Pharmacoecon & Outcomes Studies Grp, Hartford, CT USA
关键词
blood pressure; implantable cardioverter defibrillator; magnesium; ESSENTIAL-HYPERTENSION; SUPPLEMENTATION; POTASSIUM; CALCIUM; ERYTHROCYTES; DEFICIENCY; VESSELS; SODIUM; IMPACT;
D O I
10.1345/aph.1L640
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Previous studies have evaluated the impact of oral magnesium on blood pressure; however, they used magnesium salts with low bioavailability, had methodological issues, and showed differing results. OBJECTIVE: To evaluate the long-term blood pressure-lowering ability of oral magnesium L-lactate versus placebo in patients with implanted cardioverter defibrillators (ICDs). METHODS: In this double-blind, 24-week trial, 50 patients with ICDs were randomized to receive magnesium L-lactate (6 tablets daily, supplying a total of 504 mg of elemental magnesium daily) or matching placebo for at least 12 weeks. Baseline intracellular and serum magnesium concentrations were determined. The primary efficacy endpoint was the mean sitting systolic blood pressure at 24 weeks. RESULTS: In 50 patients who completed at least 12 weeks of follow-up, 86% of, patients, regardless of randomization, had a baseline intracellular magnesium deficiency, but no patients had a serum magnesium deficiency. At 12 weeks, magnesium L-lactate significantly reduced systolic blood pressure compared with placebo (117.7 +/- 11.8 vs 126.3 +/- 16.7 mm Hg, respectively; p = 0.04). In the 45 patients who continued in the study through the 24-week time period, the systolic blood pressure reduction was maintained, but statistical significance was lost (118.1 +/- 14.1 vs 125.5 +/- 17.2 mm Hg, respectively; p = 0.13). Magnesium L-lactate did not impact diastolic blood pressure at either time period (p >= 0.75 for both). Patients with a documented history of hypertension at baseline showed similar qualitative results to the primary analysis. CONCLUSIONS: A large number of subjects with ICDs have an intracellular magnesium deficiency not captured through serum magnesium determination. The use of magnesium L-lactate in patients with an ICD results in significant improvement in systolic blood pressure at 12 weeks, which may be maintained through 24 weeks.
引用
收藏
页码:569 / 576
页数:8
相关论文
共 50 条
  • [1] Elevated γ-glutamyltransferase in implantable cardioverter defibrillator patients
    Dichtl, Wolfgang
    Wolber, Thomas
    Paoli, Ursula
    Theurl, Thomas
    Bruellmann, Simon
    Stuehlinger, Markus
    Berger, Thomas
    Spuller, Karin
    Strasak, Alexander
    Pachinger, Otmar
    Haegeli, Laurent
    Duru, Firat
    Hintringer, Florian
    WIENER KLINISCHE WOCHENSCHRIFT, 2012, 124 (1-2) : 18 - 24
  • [2] INFECTIONS IN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR PATIENTS
    WUNDERLY, D
    MALONEY, J
    EDEL, T
    MCHENRY, M
    MCCARTHY, PM
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1990, 13 (11): : 1360 - 1364
  • [3] Living with an implantable cardioverter defibrillator: The patients' experience
    Humphreys, Nina K.
    Lowe, Rob
    Rance, Jaynie
    Bennett, Paul D.
    HEART & LUNG, 2016, 45 (01): : 34 - 40
  • [4] Implantable cardioverter defibrillator therapy in postinfarction patients
    Zareba, W
    CURRENT OPINION IN CARDIOLOGY, 2004, 19 (06) : 619 - 624
  • [5] ANALYSIS OF DEATHS IN PATIENTS WITH AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR
    EDEL, TB
    MALONEY, JD
    MOORE, SL
    MCALLISTER, H
    GOHN, D
    SHEWCHIK, JM
    ALEXANDER, L
    FIRSTENBERG, MS
    CASTLE, LW
    SIMMONS, TW
    WILKOFF, BL
    TROHMAN, R
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1992, 15 (01): : 60 - 70
  • [6] Use of β-Blockers in Patients with an Implantable Cardioverter Defibrillator
    LaPointe, Nancy M. Allen
    Stafford, Judith A.
    Pappas, Paul A.
    Al-Khatib, Sana M.
    Anstrorn, Kevin J.
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (7-8) : 1189 - 1196
  • [7] Assessment of Anxiety Level in Patients Receiving Implantable Cardioverter Defibrillator
    Mohammadi, Nooreddin
    Askari, Shahin
    Farahani, Mansooureh Ashghali
    Ghorbani, Azam
    Ghafarzadegan, Rezvan
    Masuomi, Nasrin
    CRESCENT JOURNAL OF MEDICAL AND BIOLOGICAL SCIENCES, 2019, 6 (01): : 13 - 17
  • [8] The Effect of Air Pollution on Ventricular Arrhythmias in Patients with Implantable Cardioverter Defibrillator
    Shahabi, Javad
    Azhari, Amirhossein
    Safari, Mohsen
    Rahimi-Pordanjani, Amin
    RESEARCH IN CARDIOVASCULAR MEDICINE, 2023, 12 (04) : 108 - 111
  • [9] Use of technology in training patients with implantable cardioverter defibrillator
    Yardimci, Tugba
    Mert, Hatice
    CLINICAL AND EXPERIMENTAL HEALTH SCIENCES, 2014, 4 (03): : 168 - 172
  • [10] Rehabilitation of patients with implantable cardioverter/defibrillator: a literature review
    Hussein, Naglaa Abdel Mohsen
    Thomas, Mark A.
    ACTA CARDIOLOGICA, 2008, 63 (02) : 249 - 257